Volumetric neuroimaging and traumatic brain injuries

Of the 1.5 million traumatic brain injuries (TBI) every year, 80% of them are considered mild. A “mild TBI”, often referred to as a concussion, is defined as loss of consciousness and/or confusion and disorientation, which is shorter than 30 minutes and an initial Glasgow Coma Scale (GCS) of 13-15.

A patient a with mild TBI does not initially present with any visible pathology, such as fractures, contusions, and hemorrhages. Long-term, however, the patient may possess disabling cognitive, psychological, and/or behavioral impairments and employment disabilities. In fact, recent studies have demonstrated that neurologic and psychiatric problems persist in 10-50% of brain trauma patients and maybe severe enough that cognitive defects never return to a pre-injury state.

Cortechs.ai | Volumetric neuroimaging and traumatic brain injuries
Graph displaying increased risk of neurodegeneration with a brain injury. Image source: Bigler, Erin D. (2013). Traumatic brain injury, neuroimaging and neurodegeneration. Frontiers in Human Neuroscience, 7(395):1-15.

Any injury to the brain can generate significant loss of brain volume, which in turn can initiate neuropathological changes, such as the presence of certain biomarkers (β-amyloid and tau), as well as neuroinflammatory changes. These changes can cause a younger aged brain to have symptoms that resemble an older neurodegenerative brain.

Cortechs.ai | Volumetric neuroimaging and traumatic brain injuries
T1-weighted coronal images displaying hippocampal atrophy, ventricular dilation and sulcal widening in both an 86 year old patient clinically diagnosed with Alzheimer’s disease and a 14 year old patient with severe TBI, as compared to a healthy 14 year old. Image source: Bigler, Erin D. (2013). Traumatic brain injury, neuroimaging and neurodegeneration. Frontiers in Human Neuroscience, 7(395):1-15.

Using MRI scans and sophisticated software tools for quantitative imaging (NeuroQuant) to analyze the resulting images has become a significant element in the assessment of patients with TBI. Volumetric MRI studies performed after a brain injury can provide physicians with regional and whole brain volumes, which can be followed over time. This is especially meaningful, as global and regional brain atrophy from a single minor brain injury or concussion, can be detected one year after the injury.

NeuroQuant is a leading medical device software that automatically and accurately segments and calculates brain structure volumes from the 3D MR images, thereby providing anatomic information about the brain in a non-invasive fashion.

For physicians evaluating TBI, the Triage Brain Atrophy report provides volume measurements of 39 left and right brain structures and indicates the patient’s brain structure volume measurements as compared to a healthy population (Cortechs.ai’ normative reference data). This information provides physicians with an accurate indication of where an individual’s brain structure volumes are compared with their age- and gender-matched peers. The Triage Brain Atrophy report provides critical supporting quantitative volumetric data to aid physicians in their assessment of TBI.


References:

[1]        Bigler, Erin D. (2013). Traumatic brain injury, neuroimaging and neurodegeneration. Frontiers in Human Neuroscience, 7(395):1-15.

[2]        Zhou, Y., Kierans, A., et al. (2013). Mild traumatic brain injury: longitudinal regional brain volume changes. Radiology: (3) 267:880-890.

More Resources

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.
Scroll to Top